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Long-term exposure to cadmium may cause
kidney and bone damage (1); the most well-
known example is the itai-itai disease in
Japan. In two earlier studies (2,3) we showed
that cadmium affects kidneys and bone at
lower levels than previously anticipated. We
also found a relationship between tubular
damage and osteoporosis. In these earlier
studies urinary cadmium was used as the dose
estimate for cadmium. Urinary cadmium is
commonly used to assess body burden of cad-
mium and has been useful in many studies
(4). However, it has been claimed that ele-
vated levels of cadmium in the urine may
reﬂect not only high levels of cadmium dose
but also renal damage (1,5,6). Cadmium in
blood mainly reﬂects recent exposure, but it
has also been shown to be a good indicator of
cadmium body burden (7,8).
It is well documented that lead can dis-
turb hemoglobin synthesis and cause behav-
ioral and neurologic disturbances in children
(9). Some epidemiologic studies have also
indicated that lead can impair kidney func-
tion (10,11). Chronic, low-level exposure to
lead has been associated with increased
excretion of low-molecular-weight proteins
and lysosomal proteins. Lead is actively
taken up and incorporated in the bone.
More than 90% of the total human body
burden of lead is in the bone (12), and lead
is also suspected to cause bone damage (13).
Lead in blood is the most frequently used
dose estimate for lead (9).
In the study area in southeastern
Sweden, nickel-cadmium batteries have been
produced since 1910 and lead batteries since
1942. Environmental cadmium and lead
pollution from these plants has been sub-
stantial in the past (14,15). The total cad-
mium emissions have been calculated to be 8
tons into the air and 32 tons into water. The
lead emission was mainly to air and was
approximately 240 tons (14). One plant was
closed in 1974, but the other is still operat-
ing. Occupational exposure to cadmium and
lead was high during the first decades of
plant operation, but has gradually decreased
since the 1960s (16,17). 
The aim of this study was to investigate
the relationship between cadmium and lead
in blood and bone mineral density (BMD)
and tubular proteinuria. 
Methods 
This study is part of the OSCAR (Osteo-
porosis—cadmium as a risk factor) study,
performed in the southeastern part of
Sweden in two communities with environ-
mental cadmium and lead pollution (2,3). A
total of 1,465 subjects, ages 16 to 80, who
had resided near the battery plant for at least
5 years between 1910 and 1992, were asked
to participate, and 904 of them (62%)
agreed to do so. 
Several workers with previous or current
occupational exposure from the two battery
plants in the study area were also included.
Out of 242 occupationally exposed workers,
117 (48%) agreed to participate in the
examinations. 
Thus, 1,021 individuals (60%) agreed to
take part in the study and gave their informed
consent to the investigation. Among the non-
participants, a telephone survey of a random
sample including 5% of the nonparticipants
gave no indication that they differed from the
examined group in a systematic way with
regard to age, sex, or morbidity.
Each study subject received a question-
naire including questions regarding employ-
ment, residence, smoking, and food habits, as
well as medical history, especially regarding
kidney diseases and diseases related to osteo-
porosis. Specially trained nurses collected
urine and blood samples and measured bone
mineral density (BMD), height, and weight. 
The presence of cadmium and lead in
blood was determined by inductively cou-
pled plasma mass spectrometry (ICP-MS). A
quadropole spectrometer (VG PQ2+; Fisons
Elemental, Winsford, Cheshire, UK)
equipped with an autosampler (Gilson 222;
Gilson, Villiers, France) was used. We used
commercial reference samples to check the
method accuracy.
We used urinary protein HC (human
complex-forming glycoprotein, formerly
called α1-microglobulin) to detect early renal
damage using single radial immunodiffusion
for the determinations. The sensitivity of the
method was 1.7 mg/L, and its total analytic
imprecision (intra-assay and interassay) was
6% (18). The analyses were made at the
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Long-term exposure to cadmium may cause kidney and bone damage. Urinary cadmium is com-
monly used as the dose estimate for the body burden of cadmium. However, elevated levels of
cadmium in the urine may reﬂect not only high levels of cadmium dose but also renal dysfunc-
tion. In this study we used blood cadmium as the dose estimate. In addition, we analyzed blood
lead. We examined 479 men and 542 women, ages 16–81 years, who were environmentally or
occupationally exposed to cadmium and lead. We used urinary protein α1-microglobulin as a
marker for tubular proteinuria and measured forearm bone mineral density using dual-energy X-
ray absorptiometry. The relationship between blood cadmium and tubular proteinuria was
strong, even when we excluded occupationally exposed participants. The subgroup with the high-
est blood cadmium levels had a 4-fold risk of tubular proteinuria compared to the subgroup with
the lowest blood cadmium levels. In the older age group (age > 60), the risk of low bone mineral
density (z-score < –1) for the subgroup with the highest blood cadmium levels was almost 3-fold
compared to the group with lowest blood cadmium levels. We found no similar associations for
lead. The observed effects may be caused by higher cadmium exposure in the past. This study
strengthens previous evidence that cadmium exposure may affect both bone mineral density and
kidney function. Key words: bone density, cadmium, environmental exposure, heavy metals, lead,
occupational exposure, osteoporosis, proteinuria. Environ Health Perspect 110:699–702 (2002).
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voided in acid-washed polyethylene bottles
and stored frozen (–20°C) until transfer to
Lund University Hospital. At the laboratory,
the sample was thawed and 10 mL urine 
was poured into a polypropylene tube.
Subsamples for the determination of protein
HC were pipetted from the sampling bottle
into separate tubes and freeze stored until
analysis. A preservative solution was added
to the subsample for protein HC determina-
tion according to Tencer et al. (19). Protein
HC was then adjusted to urinary creatinine
to account for differences in dilution of the
urine. Creatinine was measured using an
enzymatic colorimetic method using a
Hitachi Modular-P (Roche Diagnostics,
Mannheim, Germany). 
The cut-off points used for tubular pro-
teinuria were 0.8 mg protein HC/mmol cre-
atinine for men and 0.6 mg/mmole for
women, which reﬂects the upper 95% limit
in a Swedish reference population (18).
We measured bone mineral density
(BMD) in the forearm, with an ambulant
instrument (Osteometer DTX-200; Meditech
A/S, Rødovre, Denmark), using dual energy
X-ray absorptiometry (DXA), which is com-
monly used to evaluate BMD (20). We mea-
sured the nondominant arm with the patient
in a supine position. We measured the BMD
in the distal site in the forearm, which
includes both the radius and the ulna from
the 8-mm point (point where the radius and
ulna are separated by 8 mm) and 24 mm
proximally. The distal site contains 10–20%
trabecular bone (21). We checked the internal
variation by daily calibration using a phan-
tom. We compared the measured BMD to a
reference population furnished by the instru-
ment supplier (Osteometer; Meditech). The
reference population did not have any previ-
ous or present diseases known to influence
calcium metabolism. No restrictions were
made on smoking or other lifestyle habits.
The ambulant instrument was used and vali-
dated in a previous study (22).
The degree of osteoporosis can be
assessed by computing an age- and sex-stan-
dardized z-score (23). A common deﬁnition
of low bone mineral density is z-score < –1
(24), which indicates one standard deviation
below a sex- and age-standardized mean,
which is used in the present study.
Variables with a skewed distribution
were log transformed (log e) to achieve nor-
mal distribution when appropriate.
Multiple regression was used for the
multivariate analysis. Odds ratios (ORs) and
95% confidence intervals (95% CIs) were
computed using logistic regression. All the
statistical analyses were performed using the
STATA 7.0 software (Stata Corp., College
Station, TX, USA).
Results
Characteristics of the study population
regarding sex, age, blood cadmium, blood
lead, urinary excretion of protein HC,
BMD, and smoking are presented in Table
1. The smokers had been smoking regularly
for at least 1 year. 
Table 2 shows the regression coefﬁcients
for the independent variables age, blood cad-
mium, blood lead, and smoking, with log-
transformed protein HC as the dependent
variable. There was a strong positive correla-
tion between blood cadmium and age and
protein HC. No similar effect was seen for
blood lead. The results changed only mar-
ginally when analyzing blood cadmium and
blood lead separately or when smoking was
excluded. When the analyses were restricted
to environmentally exposed persons, the
results remained essentially the same. 
Another way to examine the relation is
to look at the dose–response relationship
between blood cadmium and tubular pro-
teinuria. A total of 171 people (128 environ-
mentally and 43 occupationally exposed)
had tubular proteinuria, using the above-
mentioned cut off points. Figure 1 shows the
odds ratios (with 95% CIs) for tubular pro-
teinuria for different blood cadmium groups
in the environmentally exposed group, after
adjustment for age, sex, and smoking. The
cut-off level for the lowest dose group was set
at 5 nmol/L, and this group was used as the
reference group (n = 658). The remaining
subjects were divided into four groups of
similar size (n = 84, 93, 80, 94). This pro-
duced cut-off-points for the different groups
of 5, 7, 10, and 15 nmol/L. Excess risks for
tubular proteinuria were found for all the
groups exceeding 7 nmol cadmium/L blood. 
As shown in earlier published data (2),
BMD decreases more rapidly after 55–60
years of age in both men and women. The
analyses of BMD thus focused on the older
age group (> 60 years). In Table 3, a multi-
ple linear regression is shown for the sub-
group older than 60 years, with distal BMD
as the dependent variable and age, weight,
blood cadmium, blood lead, and smoking as
independent variables. In both the whole
group and the older subgroup there was a
negative correlation between age and BMD
and a positive correlation between weight
and BMD. There was a negative correlation
between cadmium dose, expressed as blood
cadmium, for both men and women in the
older age group—signiﬁcant for women and
close to signiﬁcant for men. In contrast, we
observed no signiﬁcant trend for lead. In the
whole group (all ages), no signiﬁcant correla-
tions could be found among blood cad-
mium, lead, and BMD. Smoking did not
alter the analyses in a major way. The results
only changed marginally if blood cadmium
and blood lead were examined in separate
analyses. 
We conducted dose–response relation-
ships for the bone effects in a similar way as
for the renal effects. Table 4 shows the odds
ratios (with 95% CIs) for low bone mineral
density (z-score < –1) for three blood cad-
mium groups for people over 60 years of
age, adjusted for weight and smoking. The
z-score includes adjustment for age and sex
as described above. The cut-off level for the
lowest dose group was set at 5 nmol/L as
above. The remaining subjects were divided
into two groups of similar size (n = 177,
174). This produced cut-off points for the
different groups of 5 and 10 nmol/L.
Statistically signiﬁcant differences were seen
at blood cadmium levels > 5 nmol/L, and in
the group with blood cadmium > 10 nmol/l
the OR was 2.9 (95% CI = 1.4–5.8).
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Table 1. Characteristics of the 1,021 individuals examined in the study.
Men (n = 479) Women (n = 542)
Characteristics Mean (10th, 90th percentiles) Mean (10th, 90th percentiles)
Age 54 (range 18–81) 52 (range 16–81)
Blood Cd (nmol/L)a 7.6 (1.3, 17) 5.5 (1.5, 12)
Blood Pb (µmol/L)b 0.16 (0.08, 0.25) 0.11 (0.05, 0.17)
Urinary protein HCc (mg/mmol creatinine) 0.67 (0.16, 1.2) 0.46 (0.15, 0.8)
Distal bone mineral density (g/cm2) 0.56 (0.46, 0.67) 0.44 (0.32, 0.54)
Smokersd (% former or current) 53 43
aMissing analyses for 5 men, 7 women. bMissing analyses for 6 men, 7 women. cMissing analyses for 9 men, 9 women.
dMissing records for 3 men, 8 women.
Table 2. Multiple linear regression analysis for log transformed protein HC (mg/mmol creatinine) as a
function of age, blood-cadmium, blood-lead, and smoking. 
Mena (n = 460) Womenb (n = 521)
Characteristics Regression coefﬁcient 95% CI Regression coefﬁcient 95% CI
Age (years) 0.023 0.019–0.028 0.017 0.013–0.020
Blood Cd (nmol/L) 0.016 0.0099–0.023 0.015 0.0049–0.025
Blood Pb (µmol/L) 0.015 –0.80–0.83 –0.19 –0.99–0.60
Smoking (never or former/current) –0.042 –0.18–0.096 0.028 –0.090–0.15
R2 = 0.26. bR2 = 0.17.Discussion
Our results show that there is a relationship
between blood cadmium and tubular pro-
teinuria and low bone mineral density. We
found no similar associations for lead. The
relationship between cadmium and tubular
proteinuria is strong, even when the occupa-
tionally exposed participants are excluded.
The subgroup with the highest cadmium
levels had a 4-fold increased risk of having
tubular proteinuria compared to the sub-
group with the lowest blood cadmium levels.
In the older age group (age > 60), the risk of
low bone mineral density (z-score < –1) for
the subgroup with the highest blood cad-
mium levels was almost three times that of
the group with lowest blood cadmium levels.
It is difﬁcult to ﬁnd a perfect dose esti-
mate for cadmium and lead, as with many
other toxic agents. The dose estimate most
often used for cadmium is urinary cad-
mium. However, renal damage may lead to
a higher excretion of cadmium, as has been
shown both in animal (1,5) and in human
studies (1,6,25,26). It has been shown that
blood cadmium can be a better dose esti-
mate when tubular proteinuria is present
(27). Examination of cadmium-exposed
workers more than 15 years after the cessa-
tion of exposure showed a stronger associa-
tion between blood cadmium and tubular
proteinuria than between urinary cadmium
and tubular proteinuria (27). 
During high cadmium exposure, for
example through occupational exposure, the
cadmium concentration in blood increases
relatively rapidly. After some months, cad-
mium in blood reaches a concentration that
corresponds to the intensity of the exposure.
If the exposure stops, the blood cadmium
concentration decreases fairly rapidly, with
an initial half-time of 2–3 months (4,7).
However, cadmium accumulated in the
body will inﬂuence the blood cadmium con-
centration. Therefore, after exposure ceases,
the concentration in blood will not decrease
to the preexposure level. Thus, cadmium in
blood may serve as a good estimate of the
accumulated body burden of cadmium.
Also, in the general population, blood
cadmium is influenced largely by the body
burden of cadmium. One study on the inﬂu-
ence on blood cadmium concentrations from
various dietary factors showed no signiﬁcant
association between cadmium concentrations
in blood and duplicate diets, while body bur-
den, measured as urinary cadmium and S-fer-
ritin (measure of body iron stores) were the
main determining factors for blood cadmium
(28). A study of environmentally exposed
women in Japan also showed that blood cad-
mium correlated closely with urinary cad-
mium. Both blood and urinary cadmium
correlated in this study with cadmium in
food duplicates (copies of the food eaten by
participants during the study) (29). 
In nonsmoking, nonoccupationally
exposed individuals in Sweden, the blood
cadmium levels are usually between 0.9 and
7 nmol Cd/L, but in smokers the concentra-
tions are often considerably higher (30). A
Swedish study on an elderly population
with a mean age of 87 years showed blood
cadmium concentrations of 3.9 nmol/L in
nonsmokers and 7.5 nmol/L in current
smokers (31). A Japanese study on adult
women in an area not defined as cadmium
polluted showed mean cadmium levels in
blood of 18.9 nmol/L (32). The mean blood
cadmium levels in this study (7.6 nmol/L for
men and 5.5 nmol/L for women) are in the
upper normal limit of the general Swedish
population, but lower than in Japan. It is
important to remember that it is not possi-
ble to directly compare the blood levels in
the present study with other groups with
another exposure history. Most occupation-
ally exposed and many of the environmen-
tally exposed people in the current study had
a much more pronounced exposure earlier
when the battery plant still was operating. It
is difﬁcult to estimate which blood cadmium
levels they had, for example, 30 years ago,
although most probably they were higher.
Another problem is that the prevalence,
rather than the incidence, of tubular protein-
uria and low BMD is being analyzed. It is
not possible to say how high the exposure
was at the time when the tubular proteinuria
or the low BMD appeared. 
In a Belgian study (33) on environmen-
tally cadmium-exposed individuals, there
was a negative correlation between urinary
cadmium and forearm bone density in post-
menopausal women. The results from the
present study are in agreement with the
Belgian report, with an effect especially in
older people. In our earlier report from pro-
ject OSCAR, using urinary cadmium as the
dose estimate, the effect on the bone mineral
density was more pronounced among men
than women (2). This is in contrast to the
present study where the effect is slightly
more pronounced in women. However, it is
not only the dose estimate that differs
between the two studies; in the previous
report an additional 41 occupationally
highly exposed men and 2 women were
included. These subjects were excluded from
the present study because data were missing
on blood cadmium and lead. 
The effect of cadmium on bone mineral
density is much more pronounced in older
people (> 60 years) in the present study.
This may reﬂect that the bone is more sensi-
tive to cadmium as the bone ages. Another
possible explanation is that it takes a couple
of decades for cadmium to affect the bone.
The infamous itai-itai disease in Japan,
characterized by severe osteoporosis and
osteomalacia, was most likely caused by cad-
mium and was found almost exclusively in
older women (1).
In contrast to our ﬁndings on cadmium,
we found no associations between blood lead
and tubular proteinuria measured as protein
HC excretion. The mean blood lead levels in
Articles • Effects of cadmium and lead in blood
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Figure 1. Odds ratios (95% CIs) for prevalence of
tubular proteinuria related to blood cadmium
(B-Cd) adjusted for age, sex, and smoking for the
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Table 4. Logistic regression model for low BMD (z-score < –1) including blood cadmium and smoking as
categoric variables and weight as a continuous variable, for the subgroup older than 60 years.
Variable OR 95% CI
Blood Cd < 5 nmol/L (mean 2.5) 1 —
Blood Cd ≥ 5 nmol/L and <10 nmol/L (mean 7.2) 2.0 1.1–3.9
Blood Cd ≥ 10 nmol/L (mean 21) 2.9 1.4–5.8
Smoking 0.82 0.46–1.5
Weight 0.96 0.94–0.98
Table 3. Multiple linear regression analysis of BMD for the subgroup ages 60 years and older, as a function
of age, weight, blood cadmium, blood lead, and smoking.
Men (n = 172)a Women (n = 176)b
Characteristics Regression coefﬁcient 95% CI Regression coefﬁcient 95% CI
Age (years) –0.0035 –0.0058––0.0013 –0.0055 –0.0074––0.0035
Weight (kg) 0.0022 0.0011–0.0032 0.0026 0.0017–0.0035
Blood Cd (nmol/L) –0.00044 –0.0012–0.00035 –0.0030 –0.0054––0.00066
Blood Pb (µmol/L) –0.048 –0.20–0.10 0.078 –0.057–0.21
Smoking (never or former/current) –0.020 –0.044–0.0035 0.019 –0.0077–0.045
aR2 = 0.21. bR2 = 0.28. our study were 0.16 µmol/L for men (range
0.08, 0.25) and 0.11 µmol/L for women
(range 0.05–0.17). The levels that appeared to
be the threshold for proximal tubular injury in
both animal and human studies have been
around 3 µmol/L (11). In concordance with
the present results, other studies with lower
lead blood levels have shown negative relations
between blood lead kidney function (26).
Neither could we find any associations
between lead and distal forearm bone mineral
density. Different experimental and some
human studies have shown that lead also may
affect the bone. Studies on children have
shown negative correlations between lead in
blood and the levels of 1,25-dihydroxyvita-
min-D (34,35). Experimental studies have
shown different possible mechanisms on how
lead may affect bone (13). It is possible that
bone effects from lead exposure can occur at
higher levels than in the present study. 
Lead is often and most easily measured in
blood, and it is a commonly used indicator of
the total body burden (9). However, the half-
life of lead in blood is short, about 36 days
(9), so it typically represents mostly, but not
only, recent exposure. Lead in blood is
derived from levels in the environment and
from lead stored in tissues, mostly bone, that
reenters the blood. Maybe the results would
have been different if the total body burden
could have been better measured. Methods
for detecting low lead levels in bone with in
vivo X-ray fluorescence are now available
(36,37), but are not easily accessible. 
Thus, this report in combination with
our earlier studies (2,3) show that cadmium
exposure is related to early renal and bone
effects regardless whether urinary or blood
cadmium is used for dose estimation. The
possible effect of tubular damage on the
excretion of cadmium does not appear to
confound these ﬁndings. Lead does not seem
to be a confounder. 
It is still debated whether early renal
effects such as tubular proteinuria have any
clinical effects. However, a newly published
study from the area where this study was
performed shows that the age-standardized
rate ratio for end stage renal disease
increased from 1.4 in the low-exposure
group to 1.9 and 2.3 in the moderate- and
high-exposure groups, respectively (15). 
To summarize, we found a relationship
between low blood cadmium and tubular
proteinuria and low bone mineral density.
These associations may be caused by higher
cadmium exposure in the past. We found no
such associations for blood lead. This study
strengthens previous evidence that environ-
mental cadmium exposure may affect both
BMD and kidney function. 
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